

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

**First time genotyping of *Cryptosporidium* spp. isolates from diarrheic stools of Algerian HIV-Infected subjects supports predominant zoonotic transmission routes**

**Short title: Genotyping of *Cryptosporidium* spp. and Algerian HIV-Infected patients**

**Author names and affiliations**

**Malika Semmani<sup>1</sup>; Damien Costa<sup>2</sup>; Nassima Achour<sup>3</sup>; Meriem Cherchar<sup>1</sup>; Abdelmounaim Mouhajir<sup>2</sup>; Venceslas Villier<sup>2</sup>, Jean Jacques Ballet<sup>2</sup>; Loic Favennec<sup>2</sup>; Haiet Adjmi Hamoudi<sup>4</sup>; Romy Razakandrainibe<sup>2\*</sup>**

1: Unité de Parasitologie-Mycologie El Hadi Flici Ex.El Kettar, Alger Algeria

2: Centre National de Référence Laboratoire Expert Cryptosporidioses, Laboratoire de Parasitologie-Mycologie, CHU de Rouen ; Université de Rouen Normandie EA 7510 ESCAPE-France

3 : Service d'Infectiologie B, EHS El Hadi Flici Ex.El Kettar, Alger Algeria

4 : Service de Parasitologie-Mycologie Hopital Central De l'Armée Alger Algeria

**Corresponding author**

Romy Razakandrainibe

Email: [Romy.razakandrainibe@univ-rouen.fr](mailto:Romy.razakandrainibe@univ-rouen.fr)

Phone : +33235148655

35 **Abstract**

36 **Background**

37 *Cryptosporidium* is a significant cause of chronic diarrhoea and death in HIV-infected  
38 patients. Although HIV-infected patients under HAART have currently reduced risk of  
39 suffering from opportunistic infections, opportunistic gastrointestinal infections such  
40 as cryptosporidiosis still occur. Currently, there are no data on genetic  
41 characteristics of *Cryptosporidium* isolates from cryptosporidiosis patients in Algeria.  
42 This study was aimed at identifying *Cryptosporidium* species and subtype families  
43 prevalent in Algerian HIV-infected patients and contributing to the molecular  
44 epidemiology mapping of *Cryptosporidium* in the MENA region.

45

46 **Methods**

47 From 2016 to 2018, 350 faecal specimens were obtained from patients with an  
48 HIV/AIDS positive status associated with diarrhoea attending inpatient  
49 (hospitalisation) and outpatient care units of El Hadi Flici (ex El- Kettar) hospital,  
50 Alger city, Algeria, and screened for the presence of *Cryptosporidium* using  
51 microscopy. Positive samples were submitted to the "Centre National de Référence-  
52 Laboratoire Expert-Cryptosporidioses", Rouen University Hospital, France, for  
53 molecular analysis (species, genotype) by DNA sequencing of the *SSU18S rRNA*  
54 and *Gp60* genes, respectively.

55

56 **Results**

57 Out of 350 samples, 33 (9.4%) were microscopically positive for *Cryptosporidium*  
58 spp. of which 22 isolates were successfully amplified at the 18S rRNA and gp60 loci.  
59 Based on sequence analysis: 15 isolates were identified as *C. parvum* with family  
60 subtypes IIa-7, and II d-8, while 5 were identified as *C. hominis* (family subtypes Ia-2  
61 and Ib-3) and 2 as *C. felis*.

62

63 **Conclusion**

64 The predominance of *C. parvum* subtype families IIa and II d in this study highlights  
65 the potential importance of zoonotic cryptosporidiosis transmission to Algerian HIV-  
66 positive subjects. More extensive sampling of both humans and farm animals,  
67 especially sheep, goats and calves, and collection of epidemiological data are

68 needed for better understanding of the sources of human *C. parvum* infections in  
69 Algeria.

70

### 71 **Author summary**

72 Cryptosporidiosis, an opportunistic infection, still represents a severe threat for HIV-  
73 infected individuals. *Cryptosporidium parvum* and *Cryptosporidium hominis* are the  
74 leading cause of human cryptosporidiosis. Besides, other species and genotypes of  
75 *Cryptosporidium* might infect both immunocompetent and immunocompromised  
76 subjects.

77 In Algeria, no study has been conducted until now on the prevalence and molecular  
78 characteristics of *Cryptosporidium*-infection among HIV-infected individuals. Thus,  
79 this study aimed to examine the distribution and molecular characteristics of  
80 *Cryptosporidium* spp—isolates to provide clues to the understanding of transmission  
81 dynamics of species and genotypes to Algerian HIV-infected patients.

82 Of 350 faeces samples, 33 were microscopy-positive for *Cryptosporidium* and  
83 molecular characterisation obtained for 22 isolates resulted in the identification of *C.*  
84 *hominis*, *C. parvum*, and *C. felis*. The frequent occurrence of the zoonotic IIa and IIc  
85 subtype families of *C. parvum* was suggestive of widespread zoonotic transmission  
86 of cryptosporidiosis in Algeria, and warrants further extensive molecular  
87 epidemiological studies in both human and animal populations.

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

## 104 INTRODUCTION

105 Human Immunodeficiency Virus (HIV)-infection continues to be a significant global  
106 public health issue nowadays. End 2018, 37.9 million people were globally living with  
107 HIV/ Acquired Immune Deficiency Syndrome (AIDS) [1]. In the Middle East and  
108 North Africa (MENA) region, an extensive geographic area that extends from  
109 Morocco to Iran (encompassing approximately 22 countries), the estimated  
110 prevalence rate of adults aged 15-49 years living with HIV infection is one of the  
111 lowest in the world (less than 0.1%). In Algeria, available data indicate 11 000 to 14  
112 000 people living with HIV, among whom 68–82% had access to antiretroviral  
113 therapy [2].

114 Diarrhoea is a common clinical manifestation of HIV infection regardless of whether  
115 patients have AIDS. Indeed, one of the hardest-hit organs in HIV infected individuals  
116 is the intestinal tract. Enterocytic-HIV infection results in enterocyte atrophy and  
117 impaired functioning, destruction of gut immune cells and intestinal dysfunction are  
118 resulting in diarrhoea [3,4].

119 Diarrhoea is a significant cause of morbidity in HIV patients, and nearly 40% of those  
120 who die of AIDS experienced diarrhoea [5,6]. In HIV patients, cryptosporidiosis is an  
121 opportunistic infection and an indicator of full symptomatic AIDS [7] and was  
122 reported as the leading indicator of death in adult Kenyan patients [6,8,9].

123 Despite the availability of antiretroviral therapy (with unequal access worldwide),  
124 prevalence rates of cryptosporidiosis remain high among HIV-infected patients, as  
125 illustrated by values of 26.9 and 26.7% in Ethiopia and Iran, respectively [10,11]. In  
126 Morocco, a neighbouring country, although no data are available concerning the  
127 incidence of cryptosporidiosis in HIV-infected patients, 2 respiratory  
128 cryptosporidiosis cases were reported in this population under high active  
129 antiretroviral therapy (HAART) [12]. Therapeutic intervention leads to recovery of the  
130 CD4+T cells count in HIV/AIDS patients [13]. In a murine model, resolution of  
131 established *Cryptosporidium parvum* infection requires CD4+T cells and gamma  
132 interferon [14]. In HIV patients, CD4+T cells count  $<100$  cells/mm<sup>3</sup> were associated  
133 with susceptibility to the *Cryptosporidium* infection [15]. CD4+T cells count are useful  
134 in predicting the course of *Cryptosporidium* infection as in many other opportunistic  
135 infections [16].

136 Based on biological and molecular characteristics, 31 different *Cryptosporidium*  
137 species have been currently identified, while many other genotypes are still of  
138 uncertain taxonomic status [17,18]. With the development of molecular  
139 epidemiology, more and more data are available worldwide, enabling better  
140 knowledge of *Cryptosporidium* spp. distribution and especially its zoonotic versus  
141 anthroponotic transmission. Oocysts have been found in the faeces of many  
142 vertebrates, including domestic bovines, ovines, caprines and birds [18,19].  
143 Regarding human infection, many species of *Cryptosporidium* have already been  
144 isolated in infected patients worldwide, i.e. the widely predominant *C. hominis* and *C.*  
145 *parvum*, and *C. canis*, *C. felis*, *C. meleagridis*, *C. muris*, *C. andersoni*, *C. cuniculus*,  
146 a *Cryptosporidium* rabbit genotype, a *Cryptosporidium* cervine genotype, and *C.*  
147 *serpentis* birds [20]. Regardless of immune status, the *C. hominis* species has been  
148 reported to be the predominant species infecting humans with an anthroponotic  
149 transmission in many studies, including in Africa [20]. *C. parvum* appears to be a  
150 human-adapted zoonotic species with a possible person to person transmission [21].  
151 In addition to *C. parvum* and *C. hominis*, *C. meleagridis* infections are also relatively  
152 frequent in humans. In Africa, this species is more frequently implicated in  
153 immunocompromised populations (Up to 21% vs 10% in immunocompetent  
154 subjects) [20]. In Algeria, although the availability of information about the  
155 distribution of *Cryptosporidium* species in livestock (sheep and goats) [18, 22, 23] ,  
156 no epidemiologic report is currently available for human cryptosporidiosis. This  
157 study was aimed at providing the first description of the distribution of  
158 *Cryptosporidium* species and subtypes in a group of well-defined in Algerian HIV-  
159 infected patients.

160

## 161 **PATIENTS AND METHODS**

### 162 **Patients, faeces sampling and microscopy**

163 From 2016 to 2018, faecal specimens were obtained from 350 patients with an  
164 HIV/AIDS positive status associated with diarrhoea attending inpatient  
165 (hospitalisation) and outpatient care units at El Hadi Flici (ex El- Kettar) hospital  
166 Alger city, Algeria. After informed consent, patients filled a comprehensive  
167 questionnaire with items on age, sex, contact with animals, (pets and farm animals)  
168 and sources of drinking water. Clinical characteristics, including diarrhoea, weight  
169 loss, vomiting, abdominal pain and nausea, types of HAART drug regimens (1st line,

170 second line and third-line therapies) are detailed in table 1. Laboratory  
171 characteristics, including blood CD4+ T-cell count, were recorded by physicians in  
172 charge. Cryptosporidium microscopy-based screening was performed in El Hadi Flici  
173 Ex El- Kettar hospital, Alger city, Algeria. Faecal specimens were examined by  
174 direct microscopy before and after concentration using a modification of the methods  
175 described by Ritchie [24]. All specimens were smeared onto glass slides, stained  
176 using the modified Ziehl Nielsen and auramine techniques [25] and examined using  
177 light (1,000 X) and fluorescence (100 X and 400 X) microscopy respectively. A  
178 sample was considered *Cryptosporidium*-positive if typical oocysts of 4–6µm  
179 diameter were visible. Positive samples were transferred to the Centre National de  
180 Référence - Laboratoire expert - cryptosporidioses (CNR-LE) (Rouen University  
181 hospital, France) for molecular analysis.

## 182 **Genetic *Cryptosporidium* characterisation**

### 183 **DNA extraction**

184 DNA was extracted using the QIAamp PowerFecal DNA Kit (Qiagen, France)  
185 according to the manufacturer's recommended procedures. DNA was stored at  
186 –20°C until analysis.

### 187 **18s rRNA-based *Cryptosporidium* species identification.**

188 *Cryptosporidium* species were screened using 18S rRNA gene real-time PCR, as  
189 described elsewhere [26]. Briefly, PCR was carried out in duplicates and consisted  
190 of two duplex reactions: (i) a genus-specific PCR amplifying ~300 bp of the  
191 *Cryptosporidium* 18S rRNA gene, duplexed with a *C. parvum*-specific PCR  
192 amplifying 166 bp of the LIB13 locus, and (ii) a *C. hominis*-specific PCR amplifying  
193 169 bp of the LIB13 locus. Thermocycling conditions were as follows: 95°C for 10  
194 min, followed by 55 cycles of 95°C for 15 s and 60°C for 60 s. Data were collected  
195 from each probe channel during each 60°C annealing/extension phase. Alongside  
196 real-time PCR, genomic DNAs were subjected to PCR-based sequencing of 18s  
197 rRNA as described elsewhere [27]. A two-step nested PCR protocol was used to  
198 amplify the 18S rRNA gene (215bp). For primary PCR, the cycling protocol was:  
199 94°C for 5 min (initial denaturation), followed by 30 cycles of 94°C for 45 s  
200 (denaturation), 45°C for 2 min (annealing) and 72°C for 1.5 min (extension), with a  
201 final extension of 72°C for 10 min. For secondary PCR, the protocol was: 94°C for 5  
202 min, followed by 35 cycles of 94°C for 30s, 55°C for 30s and 72°C for 30s, with a

203 final extension of 72°C for 10 min. *C. hominis*, *C. parvum*, and no-template PCR  
204 controls were included in each run for each protocol.

### 205 **Gp60 sequence amplification**

206 Genotyping was performed by sequencing a fragment of the *Gp60* gene. Primers  
207 AL3531 and AL3533 were used in the primary PCR and primers AL3532 and  
208 LX0029 in the secondary PCR leading to amplification of a fragment of  
209 approximately 364 bp [28]. Each PCR mixture (total volume, 50 µl) contained 5 µl of  
210 10X DreamTaq Buffer, each deoxynucleoside triphosphate at a concentration of 0.2  
211 mM, each primer at a concentration of 100 nM, 2.5 U of DreamTaq polymerase, and  
212 5µL of DNA template. Also, 1.25µL of DMSO (100%) was added to the mixture. A  
213 total of 40 cycles, each consisting of 94°C for 45 s, 55°C for 45 s, and 72°C for 1  
214 min, were performed. An initial hot start at 94°C for 3 min and a final extension step  
215 at 72°C for 7 min was also included. Each amplification run included a negative  
216 control (PCR water) and two positive controls (genomic DNA from *C. parvum*  
217 oocysts purchased from Waterborne Inc., and *C. hominis* genomic DNA from a  
218 faecal specimen collected in Rouen University Hospital). Products were visualised in  
219 2% agarose gels using ethidium bromide staining, and identification was confirmed  
220 by sequencing. Positive samples were further genotyped by DNA sequencing of the  
221 *Gp60* gene amplified by a nested PCR following the protocol described elsewhere  
222 [28].

### 223 **DNA sequence analysis**

224 Sequencing was used to confirm *Cryptosporidium* species/genotypes from second-  
225 round PCR products. PCR amplicons were purified using Exonuclease I/Shrimp  
226 Alkaline Phosphatase (Exo-SAP-IT) (USB Corporation, Cleveland, USA). They were  
227 sequenced in both directions using the same PCR primers at 3.2 uM in 10 µl  
228 reactions, Big Dye™ chemistries, in ABI 3500 sequence analyser (Applied  
229 Biosystems, CA, USA). Sequence chromatograms of each strand were examined  
230 with 4peaks software and compared with published sequences in the GenBank  
231 database using BLAST ([www.ncbi.nlm.nih.gov/BLAST](http://www.ncbi.nlm.nih.gov/BLAST)).

### 232 **Consent and ethical approval**

233 The authors confirm that all the participants were apprised about the aims of the  
234 study protocol. Those aged <18 years, consents were obtained from parents or  
235 guardians. Participants were also informed of the right to refuse to participate or  
236 withdraw from the study at any time without giving any reason. This study was



237 approved by the Ethical clearance committee of the El Hadi Flici Ex El- Kettar  
238 hospital.

### 239 **Statistical analysis**

240 The results obtained were presented using tables and charts (descriptive statistics).  
241 Using R statistical software (version 3.6.3), Chi-square and Fisher's exact tests were  
242 used to check for an association between *Cryptosporidium* and factors studied.  
243 Values of  $p < 0.05$  were considered statistically significant.


244

## 245 **RESULTS**

### 246 **Clinical characteristics of patients**

247 Of individual faecal samples from 350 HIV patients examined for the presence of  
248 *Cryptosporidium* oocysts, 33 (15 female and 17 male patients) were found positive.  
249 The median age of these patients was 40 years (range 7-82 years). Reported cases  
250 were highest among patients aged 20-50 years (figure1). The major clinical  
251 symptoms consisted of watery diarrhoea in all patients (chronic in 32, intermittently  
252 in one) which might be associated with nausea, vomiting or abdominal pain (n=32).  
253 Besides, fever, asthenia and weight loss were reported in 8, 16 and 23 patients  
254 respectively. Less frequent, headache or cognitive impairment was associated with  
255 *Cryptosporidium* infection (n=5). Mean and median values of CD4+ cell counts were  
256 81.65 cells/mm<sup>3</sup> and 50 cells/mm<sup>3</sup> (range 1-512 cells/mm<sup>3</sup>) respectively. Correlation  
257 of the *Cryptosporidium* infection in HIV patients with their CD4+ cell count proved  
258 that the patient with CD4 count of <100 cells/mm<sup>3</sup> were 6.36 times more likely to  
259 have the *Cryptosporidium* infections with a  $p$ -value <0.001.

260



261



262 Figure 1. Age distribution of *Cryptosporidium*-infected HIV/AIDS patients.

263

### 264 ***Cryptosporidium* species and gp60 genotypes distribution**

265 Twenty-two of the 33 positive isolates were successfully amplified at the 18S rRNA  
266 and gp60 locus. Based on sequence analysis: *C. parvum* was identified in 15  
267 samples with family subtypes IIa (n=7), and IIc (n=8). *C. hominis* was detected in 5  
268 cases (family subtypes Ia (n=2) and Ib(n=3) and 2 patients were infected with *C.*  
269 *felis*. Heterogeneity of *Cryptosporidium* was observed, eleven subtypes were  
270 identified, including 7 *C. parvum* subtypes (IIaA14G2R1, IIaA15G2R1, IIaA16G2R1,  
271 IIaA20G1R1, IIaA21G1R1, IIcA16G1 and IIcA19G1); and 4 *C. hominis* subtypes  
272 (IaA24, IaA22R2, IbA10G2 and IbA13G3). Among *C. parvum* subtypes, IIcA16G1  
273 and IIcA19G1 had the highest occurrence followed by IIaA15G2R1. For *C. hominis*  
274 isolates, IbA13G3 was identified in 2 specimens and the other subtypes in one  
275 sample each (Table I). Unique sequences generated in this study were deposited in  
276 GenBank under accession numbers MT084775-MT084794.

### 277 ***Association between treatment status and Cryptosporidium spp infection***

278 Among the 22 patients with GP60 characterised *Cryptosporidium* spp infection, 9  
279 documented-patient reported adherence to HAART (Table 1) and distributed as  
280 follows: 1°) Four patients initiated first-line ART regimen consisting of a combination  
281 between nucleoside analogue reverse transcriptase inhibitors (NRTIs) and non-  
282 NRTIs. Lamivudine (3TC) and Efavirenz (EFV) was commonly used as the  
283 backbone in first-line therapy. HAART regimen was diverse: 3TC/EFV/Abacavir  
284 (ABC) (n=2); 3TC/EFV/ Didanosine (ddI) (n=1); and 3TC/EFV/Zidovudine (AZT)  
285 (n=1). The results of the *Gp60* subtyping showed one *C. hominis* Ib family  
286 (IbA13G3); and within *C. parvum*, 2 subtype family IIa (IIaA15G2R1 and  
287 IIaA21G1R1). 2°) Four individuals were using the second-line regimen. The favoured  
288 second-line therapy was a double boosted protease inhibitor combination regimen  
289 consisting of Darunavir (DRV) boosted with Ritonavir (RTV) in association with 3TC.  
290 Subtype IbA10G2; IIaA15G2R1; IIaA16G2R1 and IIcA16G1 were detected. 3°) *C.*  
291 *parvum* IIaA15G2R1 was identified in a patient with virologic failure on second-line  
292 ART regimen. Virologic failure represents the definition of viral non-suppression  
293 (plasma HIV RNA > 1000 copies/mL) used by the WHO Public health approach for  
294 low-and middle-income countries. As for whether it was the first or the second-line

295 regimen, no significant association was found between *Cryptosporidium* infection  
296 and HAART treatment at the species and subtype levels  
297

298 **Table 1: Socio-demographic and clinical characteristics of HIV infected patients with microscopy positive for *Cryptosporidium* spp**

299

Sex	Age intervals (years)	Duration of diarrhoea	Subtypes	CD4 (cells/mm <sup>3</sup> )	ART regimen	contact with animals	Water consumption
F	50-60	> 14days	IlaA15G2R1	26	virologic failure	Cats	Tap water
M	60-70	> 14days	IIdA19G1	45	New case	Sheep and cattle	Well water
F	NA	> 14days	IIdA19G1	20	New case	No	Tap water
F	40-50	> 14days	-	74	lost to follow-up	Cats and turtle	Tap water
M	20-30	> 14days	<i>C.felis</i>	57	New case	No	Well water
M	10-20	> 14days	<i>C.felis</i>	NA	New case	Cats and pigeons	Tap water
M	40-50	> 14days	IIdA19G1	1	New case	No	Well water
M	40-50	> 14days	IIdA16G1	172	3TC/DRV/RTV	No	Tap water
F	30-40	NA	-	106	New case	No	Tap water
M	40-50	> 14days	-	NA	3TC/EFV/AZT	Sheep and cattle	NA
F	80-90	<14days	IlaA21G1R1	512	3TC/EFV/ABC	NA	Tap water
F	30-40	NA	-	100	New case	NA	NA
M	30-40	> 14days	-	45	3TC/EFV/ABC	No	NA
F	NA	NA	IIdA19G1	NA	New case	No	NA
M	50-60	> 14days	IlaA20G1R1	55	New case	NA	Tap water
F	40-50	> 14days	IIdA16G1	16	New case	NA	NA
F	50-60	> 14days	IlaA16G2R1	40	3TC/DRV/RTV	NA	Tap water
M	30-40	> 14days	IlaA15G2R1	178	3TC/EFV/ddl	NA	Tap water
M	40-50	> 14days	IIdA16G1	92	New case	Sheep and cattle (Sheep breeder)	Well water
M	NA	> 14days	IlaA15G2R1	207	3TC/DRV/RTV	NA	NA

M	60-70	<14days	IaA14	NA	New case	Living in rural areas of farmed livestock	Tap water
F	50-60	> 14days	-	112	3TC/EFV/AZT	Cats	NA
F	30-40	> 14days	IbA10G2	9	3TC/DRV/RTV	No	Bottled water
M	20-30	> 14days	-	11	New case	No	NA
F	30-40	> 14days	-	15	New case	No	NA
F	20-30	> 14days	IlaA14G2R1	50	New case	No	Tap water
F	20-30	> 14days	IbA13G3	109	New case	No	Tap water
F	NA	> 14days	IbA13G3	47	3TC/EFV/ABC	No	Tap water
M	<10	> 14days	IaA22R2	7	3TC/EFV/AZT	No	Tap water
F	20-30	> 14days	-	111	New case	NA	Tap water
M	40-50	> 14days	IIdA16G1	53	New case	Sheep and cattle (Sheep breeder)	Well water
M	20-30	> 14days	-	50	New case	NA	NA
M	20-30	> 14days	-	48	3TC/EFV/ABC	3TC/EFV/ABC	Tap water

300 Abbreviations:

301 F: female; M: male

302 NA: not available

303 ART regimen: Lamivudine (3TC); Efavirenz (EFV); Abacavir (ABC); Didanosine (ddI); Zidovudine (AZT) ; Darunavir (DRV) ;

304 Ritonavir (RTV).

305 New case: no information was available during the investigation period as sampling was performed prior to starting antiviral

306 treatment.

307

## 308 **DISCUSSION**

309 Cryptosporidiosis is a significant cause of chronic diarrhoea and death in HIV/AIDS  
310 patients [30]. Diarrhoea occurs in 90% HIV/AIDS patients in developing countries and  
311 about 30–60% in developed countries [31,32]. Cryptosporidiosis, one of the  
312 conditions which according to the CDC classifications defines AIDS in adults and  
313 adolescents [33] and Category C: Severely symptomatic in children, is a significant  
314 cause of chronic diarrhoea in HIV/AIDS patients [34]. Of the 33 HIV-positive patients  
315 infected with characterised *Cryptosporidium* spp. in this study, thirty-one patients  
316 reported persistent chronic diarrhoea (>14 days).

317 In industrialised nations, access to HAART has significantly reduced the morbidity  
318 and mortality of cryptosporidiosis [35]. Algeria has provided HAART free of charge  
319 since 1998: standing out as one of the countries in the MENA region with the most  
320 advanced health responses. In 2016, the prevalence of HIV infected people in  
321 Algeria was about 0.1% [13 000 –15 000 individuals]. The results of the present  
322 study show a prevalence of cryptosporidiosis of 9.42% (33/350) among HIV/AIDS  
323 patients. In Tunisia, a neighbouring country, 42/526 included outpatients and  
324 inpatients presented *Cryptosporidium* spp oocysts in faeces. Of the 42 positive  
325 cases, six were found in HIV/AIDS patients [36]. Higher infection rates were reported  
326 among African HIV/AIDS patients such as in Ethiopia, Kenya, Nigeria, South Africa  
327 and Uganda with 26.9, 34, 22, 24.8 and 73.6% respectively [10,30,37-39].

328 Although there is a reduced risk of opportunistic infections in HIV-infected patients on  
329 HAART, opportunistic gastrointestinal infections may still occur. *Cryptosporidium* spp.  
330 the infection has been reported in patients with advanced immunodeficiency who are  
331 on HAART, which might explain their dyspeptic symptoms [40].

332 A CD4+ cell count below 50 is associated with severe disease. We found a mean  
333 CD4+ cell count of  $81.65 \pm 98.36$  cells/mm<sup>3</sup> and a median of 50; which is consistent  
334 with the findings of others. Despite eradication report of *Cryptosporidium* spp.  
335 infection among immunocompromised patient [35,41] and the excellent virological  
336 and immunological response with an increased CD4 absolute number over time with  
337 the use of double boosted-PI regimen plus 3TC as second-line treatment [42], in the  
338 current study, patients were not able to clear off the infection, and their CD4 counts  
339 remained below 200 cells/ mm<sup>3</sup> which aligns with previous studies [43,44].

340

341 The emergence of drug-resistant HIV variants and failure or discontinuation of  
342 HAART (as the effectiveness of HAART highly depends on how adherent patients  
343 are on their treatment), the emergence of the re-emergence of *Cryptosporidium* spp.  
344 infection in these patients should be seriously considered [45,46].

345 To our knowledge, this is the first study of the distribution of *Cryptosporidium* species  
346 and subtypes in HIV/AIDS patients in Algeria. *C. parvum* was the most common  
347 species responsible for cryptosporidiosis, followed by *C. hominis* and *C. felis*. In  
348 immunocompromised people, *C. hominis* is the most dominant species reported in  
349 Australia, Thailand, South Africa, Portugal and Peru [47]. A high diversity of *C.*  
350 *parvum* subtypes was observed in this study. Our results show that infections were  
351 marked by zoonotic isolates of *C. parvum* (subtypes IIa and IIc), suggesting that  
352 animal-to-human transmission may be a standard transmission route of  
353 *Cryptosporidium* in Algeria.

354 In the IIa family subtype, the most prevalent subtype corresponds to IIaA15G2R1  
355 (n=3/15). This subtype is the most dominant subtype infecting especially dairy cattle  
356 and has been widely reported in zoonotic infection [29,48]. As a risk factor for human  
357 cryptosporidiosis, contact with cattle or consumption of raw milk was suggested to be  
358 implicated in neighbouring countries as Tunisia [49]. Interestingly, in Algeria, this  
359 subtype has never been reported in cattle or other animals. More investigations  
360 should be performed with more substantial and more representative cattle samples in  
361 the country.

362 The IIc family is generally considered as sheep and goat subtype, even if it has  
363 already been identified in human [50,51]. Subtype IIcA16G1 (n=4/15) identified in this  
364 study was recently reported in Algerian sheep [52]. Subtype IIcA19G1 (n=4) was also  
365 detected, which previously had been reported in goats in Spain [53], in both HIV-  
366 positive patients and pre-weaned dairy cattle in China [54,55] but had never been  
367 reported in goats or other animals in Algeria. Analysis of questionnaire answers  
368 showed that 3 of 8 patients harbouring subtype IIc reported, (i) contact with animals  
369 or their excreta (living in rural areas of farmed livestock and working as a sheep  
370 breeder), and (ii) consumption of well water, a truck driver infected with *C. parvum*  
371 IIcA19G1 also noted drinking well water on his journey south. The CD4+ cell count of  
372 6 out of 8 HIV/AIDS patients harbouring family subtype IIc was under 100 cells/mm<sup>3</sup>.

373

374 Sequences analysis of *C. hominis* isolated subtypes showed the presence of IaA14,  
375 IaA22R2, IbA10G2 and IbA13G3. The IbA13G3 subtype is rarely isolated in human,  
376 but imported cases of cryptosporidiosis have already been reported in Spain [56] in  
377 HIV-positive individuals from Peru, Nigeria and Cameroon [57,58].

378 Potential zoonotic transmission to *C. felis* (n=2) was highlighted in this study. *C. felis*  
379 usually affects cats; a patient infected with this species reported, in the questionnaire,  
380 close contact with cats and birds. In Africa, reports of human infection with *C. felis*  
381 are scarce. Still, *C. felis* has been reported in HIV patients in Ethiopia [10], in HIV and  
382 non-HIV infected patients in Nigeria [43], and children under 5 years in Kenya [9].  
383 Anthroponotic transmission of *C. felis* can occur in HIV patients, particularly in areas  
384 with a high incidence of cryptosporidiosis [59].

385 In the present study, we have documented the occurrence of *Cryptosporidium*  
386 infection in HIV/AIDS patients in Algeria and the characterisation of *Cryptosporidium*  
387 subtypes. Not only the findings generated from this study improve our understanding  
388 of molecular epidemiology of cryptosporidiosis in Algeria, but they contribute to the  
389 mapping of the epidemiology of *Cryptosporidium* in the MENA region too. The  
390 predominance of the *C. parvum* family subtypes IIa and IIc in this study highlights the  
391 potential role and the importance of animals in the transmission pathway of human  
392 cryptosporidiosis. However, more extensive sampling of both humans and farm  
393 animals, especially sheep, goats and calves, and collection of epidemiological data  
394 are needed for a better understanding of the sources of *C. parvum* infections in  
395 human in Algeria.

396

#### 397 **ACKNOWLEDGMENTS**

398 The authors are grateful to Nikki Sabourin-Gibbs, Rouen University Hospital, for her  
399 help in editing the manuscript.

400

#### 401 **AUTHORS CONTRIBUTIONS**

402 Conceived and designed the experiments: SM, LF, AHH, RR. Performed the  
403 experiments: SM, AN,CM, DC, VV, RR. Analyzed the data: AM, JJB, LF, RR.  
404 Contributed reagents/materials/analysis tools: SM AHH Wrote the paper: SM, JJB,  
405 LF, RR.

406



407

408

409

## 410 REFERENCES

- 411 1. UNAIDS. 2019 Global AIDS Update: Communities at the Centre; July 2019.  
412 UNAIDS. AIDSinfo website; accessed April 2020, available  
413 from: <http://aidsinfo.unaids.org/>. UNAIDS.
- 414 2. UNAIDS region Middle East and North Africa [Cited 2020 April 1] Available  
415 from: <https://www.unaids.org/en/regionscountries/middleeastandnorthafrica>  
416
- 417 3. Craig RM, Carlson S, Ehrenpreis E. Acquired immunodeficiency syndrome  
418 enteropathy: a perspective. *Compr Ther*. 1995; 21:184–188.
- 419 4. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR. Enteropathy associated  
420 with the acquired immunodeficiency syndrome. *Ann Intern Med*. 1984;  
421 101:421–428.
- 422 5. Mwachari C, Batchelor BI, Paul J, Waiyaki PG, Gilks CF. Chronic diarrhea  
423 among HIV-infected adult patients in Nairobi, Kenya. *J Infect*. 1998; 37:48–  
424 53.
- 425 6. Mwachari CW, Meier AS, Muyodi J, Gatei W, Waiyaki P, Cohen CR. Chronic  
426 diarrhea in HIV-1-infected adults in Nairobi, Kenya: evaluation of risk factors  
427 and the WHO treatment algorithm. *AIDS*. 2003; 17:2124–2126.
- 428 7. Shrivastava AK, Kumar S, Smith WA, Sahu PS. Revisiting the global problem  
429 of cryptosporidiosis and recommendations. *Trop Parasitol*. 2017 Jan-  
430 Jun;7(1):8-17. doi: 10.4103/2229-5070.202290.
- 431 8. Mirza NB, Bhatt KM, Bhatt SM, Kanja C. Cryptosporidiosis in HIV positive  
432 patients at Kenyatta National Hospital, Nairobi, Kenya. *East Afr Med J*. 1994;  
433 71:334–335.
- 434 9. Gatei W, Wamae CN, Mbae C, Waruru A, Mulinge E, Waithera T, Gatika SM,  
435 Kamwati SK, Revathi G, Hart CA. Cryptosporidiosis: prevalence, genotype  
436 analysis, and symptoms associated with infections in children in Kenya. *Am J*  
437 *Trop Med Hyg*. 2006; 75:78–82.
- 438 10. Adamu H, Petros B, Zhang G, Kassa H, Amer S, Ye J, Feng Y, Xiao  
439 L. Distribution and clinical manifestations of *Cryptosporidium* species and

- 440 subtypes in HIV/AIDS patients in Ethiopia. PLoS Negl Trop Dis. 2014 Apr  
441 17;8(4):e2831. doi: 10.1371/journal.pntd.0002831.
- 442 11. Taherkhani H, Fallah M, Jadidian K, Vaziri S. A Study on the Prevalence of  
443 Cryptosporidium in HIV Positive Patients. J Res Health Sci. 2007 Dec  
444 28;7(2):20-4.
- 445 12. Tali A, Addebous A, Asmama S, Chabaa L, Zougaghi L. Respiratory  
446 cryptosporidiosis in two patients with HIV infection in a tertiary care hospital in  
447 Morocco. Ann Biol Clin (Paris). 2011 Sep-Oct;69(5):605-8. doi:  
448 10.1684/abc.2011.0626.
- 449 13. Hunter PR, Nichols G. Epidemiology and clinical features of Cryptosporidium  
450 infection in immunocompromised patients. Clin Microbiol Rev. 2002  
451 Jan;15(1):145-54. Review.
- 452 14. Chen W, Harp JA, Harmsen AG. Requirements for CD4+ cells and gamma  
453 interferon in resolution of established Cryptosporidium parvum infection in  
454 mice. Infect Immun. 1993 Sep;61(9):3928-32.
- 455 15. Rashmi KS, Kumar KLR. Intestinal Cryptosporidiosis and the Profile of the  
456 CD4 Counts in a Cohort of HIV Infected Patients. J Clin Diagn Res. 2013  
457 Jun;7(6):1016-20. doi: 10.7860/JCDR/2013/5339.3062.
- 458 16. Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK,  
459 Modin GW, Feigal DW, Cusick PS, Sande MA. Natural history of disseminated  
460 Mycobacterium avium complex infection in AIDS. J Infect Dis. 1991  
461 Nov;164(5):994-8.
- 462 17. Ryan U, Fayer R, Xiao L. Cryptosporidium species in humans and animals:  
463 current understanding and research needs. Parasitology.  
464 2014;141(13):1667-85.
- 465 18. Benhouda D, Hakem A, Sannella AR, Benhouda A, Cacciò SM. First  
466 molecular investigation of Cryptosporidium spp. in young calves in Algeria.  
467 Parasite Paris Fr. 2017; 24:15.
- 468 19. Elkarim Laatamna A, Holubova N, Sak B, Kvac M. Cryptosporidium  
469 meleagridis and C. baileyi (Apicomplexa) in domestic and wild birds in Algeria.  
470 Folia Parasitol (Praha). 2017;64.

- 471 20. Aldeyarbi HM, Abu El-Ezz NMT, Karanis P. Cryptosporidium and  
472 cryptosporidiosis: the African perspective. *Environ Sci Pollut Res Int.*  
473 2016;23(14):13811-21.
- 474 21. Morse TD, Nichols R a. B, Grimason AM, Campbell BM, Tembo KC, Smith  
475 HV. Incidence of cryptosporidiosis species in paediatric patients in Malawi.  
476 *Epidemiol Infect.* 2007;135(8):1307-15.
- 477 22. Laathamna AE, Wagnerová P, Sak B, Květoňová D, Xiao L, Rost M, et al.  
478 Microsporidia and Cryptosporidium in horses and donkeys in Algeria:  
479 detection of a novel Cryptosporidium hominis subtype family (Ik) in a horse.  
480 *Vet Parasitol.* 2015;208(3-4):135-42.
- 481 23. Baroudi D, Khelef D, Goucem R, Adjou KT, Adamu H, Zhang H, et al.  
482 Common occurrence of zoonotic pathogen Cryptosporidium meleagridis in  
483 broiler chickens and turkeys in Algeria. *Vet Parasitol.* 2013;196(3-4):334-40.
- 484 24. Pereira da Fonseca, I. M. Contribuicao para o estudo da criptosporidiose  
485 animal em Portugal: caracterizacao genetica de isolados de Cryptosporidium  
486 parvum de origem bovina. PhD Thesis, Faculdade de Medicina Veterinaria,  
487 Universidade Tecnica de Lisboa, 2000. 290 p.
- 488 25. Khurana S, Sharma P, Sharma A, Malla N. Evaluation of Ziehl-Neelsen  
489 staining, auramine phenol staining, antigen detection enzyme linked  
490 immunosorbent assay and polymerase chain reaction, for the diagnosis of  
491 intestinal cryptosporidiosis. *Trop Parasitol.* 2012 Jan;2(1):20-3.
- 492 26. Hadfield SJ, Robinson G, Elwin K, Chalmers RM. Detection and differentiation  
493 of Cryptosporidium spp. in human clinical samples by use of real-time PCR. *J*  
494 *Clin Microbiol.* 2011;49(3):918-24.
- 495 27. Koehler AV, Korhonen PK, Hall RS, Young ND, Wang T, Haydon SR, Gasser  
496 RB. Use of a bioinformatic-assisted primer design strategy to establish a new  
497 nested PCR-based method for Cryptosporidium. *Parasit Vectors.* 2017  
498 ;10(1):509.
- 499 28. Glaberman S, Moore JE, Lowery CJ, Chalmers RM, Sulaiman I, Elwin K,  
500 Rooney PJ, Millar BC, Dooley JS, Lal AA, Xiao L. Three drinking-water-  
501 associated cryptosporidiosis outbreaks, Northern Ireland. *Emerg Infect Dis.*  
502 2002;8(6):631-3.

- 503 29. Sulaiman IM, Hira PR, Zhou L, Al-Ali FM, Al-Shelahi FA, Shweiki HM, Iqbal J,  
504 Khalid N, Xiao L. Unique endemicity of cryptosporidiosis in children in Kuwait.  
505 J Clin Microbiol. 2005;43(6):2805-9.
- 506 30. Tumwine JK, Kekitiinwa A, Bakeera-Kitaka S, Ndeezi G, Downing R, Feng X,  
507 Akiyoshi DE, Tzipori S. Cryptosporidiosis and microsporidiosis in Ugandan  
508 children with persistent diarrhea with and without concurrent infection with the  
509 human immunodeficiency virus. Am J Trop Med Hyg. 2005 Nov;73(5):921-5.
- 510 31. Framm SR, Soave R. Agents of diarrhea. Med Clin North Am. 1997  
511 ;81(2):427-47.
- 512 32. Shimelis T, Tassachew Y, Lambiyo T. Cryptosporidium and other intestinal  
513 parasitic infections among HIV patients in southern Ethiopia: significance of  
514 improved HIV-related care. Parasit Vectors. 2016;9(1):270.
- 515 33. Centers for Disease Control (CDC). Revision of the CDC surveillance case  
516 definition for acquired immunodeficiency syndrome. Council of State and  
517 Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.  
518 MMWR Suppl. 1987 Aug 14;36(1):1S-15S.
- 519 34. 1994 Revised Classification System for Human Immunodeficiency Virus  
520 Infection in Children Less Than 13 Years of Age. Arch  
521 Dermatol. 1994;130(12):1485–1486.  
522 doi:10.1001/archderm.1994.01690120017001
- 523 35. Miao YM, Awad-El-Kariem FM, Franzen C, Ellis DS, Müller A, Counihan HM,  
524 Hayes PJ, Gazzard BG. Eradication of cryptosporidia and microsporidia  
525 following successful antiretroviral therapy. J Acquir Immune Defic Syndr. 2000  
526 Oct 1;25(2):124-9.
- 527 36. Essid R, Menotti J, Hanen C, Aoun K, Bouratbine A. Genetic diversity of  
528 Cryptosporidium isolates from human populations in an urban area of  
529 Northern Tunisia. Infect Genet Evol. 2018 ;58:237-242.
- 530 37. Wanyiri JW, Kanyi H, Maina S, Wang DE, Steen A, Ngugi P, Kamau T,  
531 Waithera T, O'Connor R, Gachuhi K, Wamae CN, Mwamburi M, Ward HD.  
532 Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features,  
533 epidemiology, molecular characterization and antibody responses. Am J Trop  
534 Med Hyg. 2014 Aug;91(2):319-28. doi: 10.4269/ajtmh.13-0254.
- 535 38. Amoo JK, Akindele AA, Amoo AOJ, Efunshile AM, Ojurongbe TA, Fayemiwo  
536 SA, Thomas BN, Ojurongbe O. Prevalence of enteric parasitic infections

- 537 among people living with HIV in Abeokuta, Nigeria. *Pan Afr Med J.* 2018 May  
538 28;30:66. doi:10.11604/pamj.2018.30.66.13160.
- 539 39. Leav BA, Mackay MR, Anyanwu A, O' Connor RM, Cevallos AM, Kindra G,  
540 Rollins NC, Bennish ML, Nelson RG, Ward HD. Analysis of sequence diversity  
541 at the highly polymorphic Cpgp40/15 locus among *Cryptosporidium* isolates  
542 from human immunodeficiency virus-infected children in South Africa. *Infect*  
543 *Immun.* 2002 Jul;70(7):3881-90.
- 544 40. Werneck-Silva AL, Prado IB. Dyspepsia in HIV-infected patients under highly  
545 active antiretroviral therapy. *J Gastroenterol Hepatol.* 2007 Nov;22(11):1712-  
546 6.
- 547 41. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-  
548 associated microsporidiosis and cryptosporidiosis with combination  
549 antiretroviral therapy. *Lancet.* 1998 Jan 24;351(9098):256-61.
- 550 42. Rusconi S, Giacomet V, Mameli C, Viganò A, Viganò O, Adorni F, Galli M,  
551 Zuccotti GV. Efficacy and safety of a dual boosted protease inhibitor-based  
552 regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a  
553 pediatric population. *BMC Infect Dis.* 2012 Aug 6;12:179.
- 554 43. Akinbo FO, Okaka CE, Omoregie R. Prevalence of intestinal parasitic  
555 infections among HIV patients in Benin City, Nigeria. *Libyan J Med.* 2010;5.
- 556 44. Ayinmode AB, Zhang H, Dada-Adegbola HO, Xiao L. *Cryptosporidium hominis*  
557 subtypes and *Enterocytozoon bienersi* genotypes in HIV-infected persons in  
558 Ibadan, Nigeria. *Zoonoses Public Health.* 2014 ;61(4):297-303.
- 559 45. Maggi P, Larocca AM, Quarto M, Serio G, Brandonisio O, Angarano G,  
560 Pastore G. Effect of antiretroviral therapy on cryptosporidiosis and  
561 microsporidiosis in patients infected with human immunodeficiency virus type  
562 1. *Eur J Clin Microbiol Infect Dis.* 2000 ;19(3):213-7.
- 563 46. Nannini EC, Okhuysen PC. HIV1 and the gut in the era of highly active  
564 antiretroviral therapy. *Curr Gastroenterol Rep.* 2002 ;4(5):392-8.
- 565 47. Widmer G, Sullivan S. Genomics and population biology of *Cryptosporidium*  
566 species. *Parasite Immunol.* 2012 Feb-Mar;34(2-3):61-71.
- 567 48. Feng Y, Torres E, Li N, Wang L, Bowman D, Xiao L. Population genetic  
568 characterisation of dominant *Cryptosporidium parvum* subtype IIaA15G2R1.  
569 *Int J Parasitol.* 2013 Dec;43(14):1141-7.

- 570 49. Rahmouni I, Essid R, Aoun K, Bouratbine A. Glycoprotein 60 diversity in  
571 *Cryptosporidium parvum* causing human and cattle cryptosporidiosis in the  
572 rural region of Northern Tunisia. *Am J Trop Med Hyg.* 2014 Feb;90(2):346-50.
- 573 50. Quílez J, Vergara-Castiblanco C, Monteagudo L, del Cacho E, Sánchez-  
574 Acedo C. Host association of *Cryptosporidium parvum* populations infecting  
575 domestic ruminants in Spain. *Appl Environ Microbiol.* 2013 Sep;79(17):5363-  
576 71.
- 577 51. Alves M, Xiao L, Antunes F, Matos O. Distribution of *Cryptosporidium*  
578 subtypes in humans and domestic and wild ruminants in Portugal. *Parasitol*  
579 *Res.* 2006;99(3):287-92
- 580 52. Sahraoui L, Thomas M, Chevillot A, Mammeri M, Polack B, Vallée I, Follet J,  
581 Ain-Baaziz H, Adjou KT. Molecular characterization of zoonotic  
582 *Cryptosporidium* spp. and *Giardia duodenalis* pathogens in Algerian sheep.  
583 *Vet Parasitol Reg Stud Reports.* 2019 Apr;16:100280. doi:  
584 10.1016/j.vprsr.2019.100280.
- 585 53. Quílez J, Torres E, Chalmers RM, Hadfield SJ, Del Cacho E, Sánchez-Acedo  
586 C. *Cryptosporidium* genotypes and subtypes in lambs and goat kids in Spain.  
587 *Appl Environ Microbiol.* 2008 Oct;74(19):6026-31
- 588 54. Wang L, Zhang H, Zhao X, Zhang L, Zhang G, Guo M, Liu L, Feng Y, Xiao L.  
589 Zoonotic *Cryptosporidium* species and *Enterocytozoon bieneusi* genotypes in  
590 HIV-positive patients on antiretroviral therapy. *J Clin Microbiol.*  
591 2013;51(2):557-63.
- 592 55. Wang RJ, Li JQ, Chen YC, Zhang LX, Xiao LH. Widespread occurrence of  
593 *Cryptosporidium* infections in patients with HIV/AIDS: Epidemiology, clinical  
594 feature, diagnosis, and therapy. *Acta Trop.* 2018; 187:257-263.
- 595 56. Merino FJ, Köster PC, Fuentes I, Carmena D. Imported cryptosporidiosis  
596 caused by *Cryptosporidium hominis* IbA13G3 in Spain. The relevance of  
597 molecular-based surveillance. *Enferm Infecc Microbiol Clin.* 2018 Dec 21. pii:  
598 S0213-005X(18)30381-1.
- 599 57. Ayinmode AB, Fagbemi BO, Xiao L. Molecular characterization of  
600 *Cryptosporidium* in children in Oyo State, Nigeria: implications for infection  
601 sources. *Parasitol Res.* 2012 Jan;110(1):479-81.
- 602 58. Cama VA, Ross JM, Crawford S, Kawai V, Chavez-Valdez R, Vargas D, Vivar  
603 A, Ticona E, Navincopa M, Williamson J, Ortega Y, Gilman RH, Bern C, Xiao

604 L. Differences in clinical manifestations among *Cryptosporidium* species and  
605 subtypes in HIV-infected persons. *J Infect Dis.* 2007 Sep 1;196(5):684-91.  
606 59. Cama V, Gilman RH, Vivar A, Ticona E, Ortega Y, Bern C, Xiao L. Mixed  
607 *Cryptosporidium* infections and HIV. *Emerg Infect Dis.* 2006 Jun;12(6):1025-8.  
608